Safe Fertility vs Tenet Healthcare: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Safe Fertility Group Public Company Limited (SAFE.BK)

Q3 202620 Jul – 6 Oct 2026

▲3▼1

SAFE bets on surrogacy law, NHSO tie-up and 2027 growth despite Q2 profit dip

Q2 profit slipped year-on-year SAFE's second-quarter 2026 net profit fell to 29.39 million baht from 34.00 million a year earlier, and first-half profit eased to 63.36 million baht. A weaker bottom line is a real counterweight to the growth story and can hold the share price back.
It is the main negative fact in the period and the honest counterweight to the bullish plans.
New Chiang Rai lab and technology push SAFE is opening a new IVF laboratory at Chiang Rai Prachanukroh Hospital in October 2026, widening access to treatment in the north. It is also promoting PGTSeq-A genetic testing technology that raises pregnancy rates and cuts miscarriages, supporting demand.
It is a concrete new capacity and technology step that can lift patient numbers and revenue.
Brokers see cheap valuation and surrogacy upside Krungsri Securities rates SAFE a buy with a 9.80 baht target, calling it cheap below book value and a play on relaxed surrogacy rules that would expand the market and raise value per case. Finansia keeps a hold at 7.25 baht, noting a slow IVF recovery and geopolitical pressure on foreign patients.
It shows the analyst view driving sentiment, including the cautious counterpoint.
NHSO NIPT talks and 2027 growth plan SAFE is in talks with the NHSO to provide NIPT fetal screening, with clarity expected next year, and targets 10-15% yearly revenue growth from 2027 while growing its family care base from 40,000 to 50,000. It also eyes Bangladesh and Indonesia.
It is the newest concrete plan for new revenue channels and long-term growth.

August 202620 Jul – 6 Oct 2026

▲3▼1

SAFE bets on surrogacy law, NHSO tie-up and 2027 growth despite Q2 profit dip

Q2 profit slipped year-on-year SAFE's second-quarter 2026 net profit fell to 29.39 million baht from 34.00 million a year earlier, and first-half profit eased to 63.36 million baht. A weaker bottom line is a real counterweight to the growth story and can hold the share price back.
It is the main negative fact in the period and the honest counterweight to the bullish plans.
New Chiang Rai lab and technology push SAFE is opening a new IVF laboratory at Chiang Rai Prachanukroh Hospital in October 2026, widening access to treatment in the north. It is also promoting PGTSeq-A genetic testing technology that raises pregnancy rates and cuts miscarriages, supporting demand.
It is a concrete new capacity and technology step that can lift patient numbers and revenue.
Brokers see cheap valuation and surrogacy upside Krungsri Securities rates SAFE a buy with a 9.80 baht target, calling it cheap below book value and a play on relaxed surrogacy rules that would expand the market and raise value per case. Finansia keeps a hold at 7.25 baht, noting a slow IVF recovery and geopolitical pressure on foreign patients.
It shows the analyst view driving sentiment, including the cautious counterpoint.
NHSO NIPT talks and 2027 growth plan SAFE is in talks with the NHSO to provide NIPT fetal screening, with clarity expected next year, and targets 10-15% yearly revenue growth from 2027 while growing its family care base from 40,000 to 50,000. It also eyes Bangladesh and Indonesia.
It is the newest concrete plan for new revenue channels and long-term growth.

Latest20 Jul – 6 Oct 2026

▲3▼1

SAFE bets on surrogacy law, NHSO tie-up and 2027 growth despite Q2 profit dip

Q2 profit slipped year-on-year SAFE's second-quarter 2026 net profit fell to 29.39 million baht from 34.00 million a year earlier, and first-half profit eased to 63.36 million baht. A weaker bottom line is a real counterweight to the growth story and can hold the share price back.
It is the main negative fact in the period and the honest counterweight to the bullish plans.
New Chiang Rai lab and technology push SAFE is opening a new IVF laboratory at Chiang Rai Prachanukroh Hospital in October 2026, widening access to treatment in the north. It is also promoting PGTSeq-A genetic testing technology that raises pregnancy rates and cuts miscarriages, supporting demand.
It is a concrete new capacity and technology step that can lift patient numbers and revenue.
Brokers see cheap valuation and surrogacy upside Krungsri Securities rates SAFE a buy with a 9.80 baht target, calling it cheap below book value and a play on relaxed surrogacy rules that would expand the market and raise value per case. Finansia keeps a hold at 7.25 baht, noting a slow IVF recovery and geopolitical pressure on foreign patients.
It shows the analyst view driving sentiment, including the cautious counterpoint.
NHSO NIPT talks and 2027 growth plan SAFE is in talks with the NHSO to provide NIPT fetal screening, with clarity expected next year, and targets 10-15% yearly revenue growth from 2027 while growing its family care base from 40,000 to 50,000. It also eyes Bangladesh and Indonesia.
It is the newest concrete plan for new revenue channels and long-term growth.

Tenet Healthcare Corporation (THC)

Q3 202621 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

August 202621 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

Latest21 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.